REGENXBIO Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Mailing Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Phone
240-552-8181
Fiscal Year End
1231
EIN
471851754
Financial Overview
FY2025
$311.74M
Stockholders' Equity
$57.53M
Cash & Equivalents
$-3.76
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Proprietary NAV® Technology Platform is proven, widely adopted, and a cornerstone for gene therapies, having delivered treatments to thousands of patients.
- Strategic partnerships with industry leaders like Novartis, AbbVie, and Nippon Shinyaku generate significant royalty revenue, potential milestones, and validate the platform's value.
Material Events
8-K
Other
March 5, 2026
High Impact
- Positive Phase 1/2 data for RGX-202 (Duchenne Muscular Dystrophy) showing an average 4.4-point increase in NSAA scores and sustained microdystrophin expression.
- Progress in eye disease treatments (sura-vec) with upcoming Phase 2 data for wet AMD in late 2026 and a $100 million milestone payment from AbbVie expected in Q2 2026.
8-K
Other
February 10, 2026
High Impact
- REGENXBIO is committed to finding a path forward for RGX-121 despite the setback.
- The company has approximately $400 million in cash and equivalents, providing some financial runway.
8-K
Other
January 28, 2026
High Impact
- Targeting severe, rare genetic disorders (MPS I and MPS II) with desperately needed treatments.
- RGX-111 and RGX-121 are crucial assets in its pipeline.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.